Log in or Sign up for Free to view tailored content for your specialty!
Skin Disorders News
Atopic dermatitis significantly impacts adults, AAD presenter reports
While atopic dermatitis is commonly diagnosed in infancy and early childhood, it can have a profound impact on adult patients, according to a presentation at the American Academy of Dermatology Summer Meeting in New York.
Topical corticosteroid phobia in atopic dermatitis tied to nonadherence
Patients with atopic dermatitis reported topical corticosteroid phobia, which appeared to play a role in nonadherence to treatment, according to recently published study results in JAMA Dermatology.
Log in or Sign up for Free to view tailored content for your specialty!
Phase 2a study shows efficacy for atopic dermatitis treatment
Glenmark Pharmaceuticals has announced positive data from its phase 2a study of GBR 830, an investigational anti-OX40 monoclonal antibody for treating atopic dermatitis.
Dupixent receives European positive opinion for treating adults with atopic dermatitis
Regeneron Pharmaceuticals and Sanofi announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has given a positive opinion for the marketing authorization of Dupixent in Europe for adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
Disease burden of atopic dermatitis comparable to psoriasis
Patients with atopic dermatitis had health-related quality of life and productivity impairment that was comparable to patients with psoriasis, according to recently published study results in the Journal of the American Academy of Dermatology.
Atopic dermatitis associated with ocular disease risk
Adults with atopic dermatitis had a significantly higher risk of developing conjunctivitis, keratitis and keratoconus compared with the general population, according to recently published study results in the Journal of the American Academy of Dermatology.
Phase 3 study of tralokinumab for atopic dermatitis begins
LEO Pharma announced that the first patients have been dosed in a phase 3 study of tralokinumab for treating moderate-to-severe atopic dermatitis.
Recent developments in allergy, asthma care during the height of the season
The Asthma and Allergy Foundation of America designates May as National Asthma and Allergy Awareness Month each year to raise awareness for these common diseases, as it is peak season for both conditions.
Vitamin D unlikely to lower risk of asthma, atopic dermatitis
Increasing vitamin D is unlikely to reduce the risk of pediatric and adult asthma, atopic dermatitis or other allergies, according to study results recently published in PLOS Medicine
No benefit seen from silk clothing in reducing eczema symptoms
Wearing silk garments is not likely to lessen moderate to severe pediatric eczema or prevent infection, according to research published in PLOS Medicine.
-
Headline News
‘Truly alarming’: Life expectancy gap in the US now up to 20 years
November 22, 20243 min read -
Headline News
Autoantibodies present in long COVID, but not a ‘smoking gun’ for new autoimmune disease
November 25, 20242 min read -
Headline News
Cardiovascular disease deaths rising among younger adults living in rural areas
November 15, 20243 min read
-
Headline News
‘Truly alarming’: Life expectancy gap in the US now up to 20 years
November 22, 20243 min read -
Headline News
Autoantibodies present in long COVID, but not a ‘smoking gun’ for new autoimmune disease
November 25, 20242 min read -
Headline News
Cardiovascular disease deaths rising among younger adults living in rural areas
November 15, 20243 min read